- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03594981
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
Adoptive Cord Blood ImmunotHerapy Using Expanded Cord Blood T Cells for EBV, CMV, BKV and Adenovirus Reactivation/Infection or ProphylaxiS
This Phase I-II dose-finding trial to determine the optimal dose of intravenous (IV) injection dose of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV and Adenovirus. A maximum of 36 patients will be treated in up to 18 cohorts each of size 2, with the first cohort treated at the lowest dose level 1, all successive doses chosen by the EffTox method, and no untried dose level skipped when escalating.
The scientific goal of the trial is to determine an optimal IV-CTL cell dose level among the three doses 1.0x107cells/m2, 2 x107cells/m2 and 5x107cells/m2., hereafter dose levels 1, 2, 3. Dose-finding will be done using the sequentially adaptive EffTox trade-off-based design of Thall et al.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase I-II dose-finding trial to determine the optimal dose of intravenous (IV) injection dose of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV and Adenovirus. A maximum of 36 patients will be treated in up to 18 cohorts each of size 2, with the first cohort treated at the lowest dose level 1, all successive doses chosen by the EffTox method, and no untried dose level skipped when escalating.
The scientific goal of the trial is to determine an optimal IV-CTL cell dose level among the three doses 1.0x107cells/m2, 2 x107cells/m2 and 5x107cells/m2., hereafter dose levels 1, 2, 3. Dose-finding will be done using the sequentially adaptive EffTox trade-off-based design of Thall et al. To implement the design's model using the latest EffTox version 4.0.12 program, doses will coded numerically to be 1, 2, 3.
CMV/AdV /EBV/BKV specific T cells will be thawed and given or thawed and diluted into a total volume of 10 mL of Plasmalyte A by slow intravenous injection over 1-2 minutes. This is a traditional Phase I dose escalation study of a single infusion of CMV/AdV/EBV/BKV-specific CTLs to patients at risk for CMV and EBV reactivation and Adenoviral and BK virus infection after umbilical cord blood transplantation. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2. There will be 2-6 patients at each dose level (depending on toxicity) following the scheme below. The decision on whether it is safe to escalate to next dose level or not will be made after at least two patients in each dose level have finished their 45-days toxicity follow up. If the first two patients have not finished their 45 days follow-up, up to 2 additional incoming patients can be enrolled at the current dose level. In addition, we will give the option of administering 2 additional doses (at the same dose level), 28 days after the first infusion of the same dose, in subjects who have a partial response after one dose or who have received other therapy that may affect the persistence or function of the infused CTL in vivo. If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
Dose Levels and Dosing Schedule
Dose Level CTL Dose Given from Day +30 post SCT
- 1x107/m2
- 2.0x107/m2
- 5x107/m2
Escalation of Multi-virus-specific CTL infusions
CMV/AdV/EBV/BKV CTL will be given from day +30 either as prophylaxis or treatment for CMV, EBV, BK and/or adenovirus infection. If the patient has viral reactivation or evidence of CMV/EBV/AdV/BKV disease (e.g. pneumonitis, gastroenteritis and/or retinitis or Post Transplant Lymphoproliferative Disorder (PTLD) or hemorrhagic cystitis the CTL can be given with concurrent antiviral pharmacotherapy.
A dose escalation scheme utilizing cohorts of two patients will be used
Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm described in Section 9 will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
The Optimal Dose of Infused CMV/AdV/EBV/BKV-Specific CTL
After all patients in the trial have been evaluated, the optimal dose of infused CMV/AdV/EBV-specific CTL will be determined by the algorithm using the sequentially adaptive EffTox trade-off-based design of Thall et al.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Allistair Abraham, MD
- Phone Number: 202-476-5772
- Email: AAbraham@childrensnational.org
Study Contact Backup
- Name: Fahmida Hoq, MBBS, MS
- Phone Number: 202-476-334
- Email: fhoq@childrensnational.org
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Recruiting
- Children's National Health System
-
Contact:
- Fahmida Hoq, MBBS, MS
- Phone Number: 202-476-3634
- Email: fhoq@childrensnational.org
-
Principal Investigator:
- Allistair Abraham, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M.D. Anderson Cancer Center (MDACC)
-
Principal Investigator:
- Amanda Olson, MD
-
Contact:
- Amanda Olson, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Inclusion Criteria at the Time of Procurement
- Pediatric and adult patients (there are no lower and upper age limits for patients) with malignant or nonmalignant diseases who are candidates for transplant.
Patients must have a CB unit (or units) matched with the patient at 4, 5, or 6/6 HLA class I (serological) and II (molecular) antigens. The unit selected for CTL expansion must be either:
- be cryopreserved in two fractions, with a minimum of 2.5x107 total nucleated cells (TNC) per kg pre-thaw in the fraction which will be used for the primary transplant. The remaining fraction will be used to generate the CTLs to give at day 30 or beyond as described below. OR
- be cryopreserved with a cell dose that totals > 3x10e7 TNC per kg pre thaw. On thaw, 20% of the total volume will be used for CTL manufacture to give at day 30 or beyond and the remaining 80% will be used for the primary transplant.
- For recipients of double CBT, if possible both CB units should be cryopreserved in two fractions and T-cells will be made from both units if possible.
Inclusion Criteria at the Time of CTL Infusion
- Recipients of at least one unmanipulated cord blood unit as described above (i.e. from a HLA matched or mismatched unrelated donor) transplant at risk for or with CMV/Adenoviral/BKV and/or EBV infection or reactivation.
- Lansky/Karnofsky scores ≥60
- Absolute neutrophil count (ANC) greater than 500/u
- No evidence of GVHD > Grade II at time of enrollment
- Life expectancy > 30 days
- Absence of severe renal disease (Creatinine < 3x normal for age)
- Absence of severe hepatic disease. Direct bilirubin must be < 3 mg/dl and AST < 5x upper limit of normal
- Patient must be at least 30 days post transplant to be eligible to receive CTL
- Written informed consent and/or signed assent line from patient, parent or guardian
Exclusion Criteria:
Exclusion Criteria at the Time of Procurement
- Pregnant or lactating
- Patients with active central nervous system disease
- Patients with Karnofsky performance status <70%
- Patients with grade 3 or 4 or primary myelofibrosis
- Patients with suitable related donors Exclusion Criteria at the Time of CTL Infusion
- Pregnant or lactating
- Patient on Fi02 of >60%
- Unable to wean steroids to ≤0.5 mg/kg/day prednisone or equivalent
- Patients with Grade 3 hyperbilirubinemia
- Patients with other uncontrolled infections (except CMV and/or adenovirus and/or EBVemia and/or BK viruria/viremia). For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- Patients with less than 50% donor chimerism in either peripheral blood or bone marrow or patients with relapse of original disease
- Patients who have received investigational (IND) product within 28 days of screening for CTL infusion under this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CMV/AdV /EBV/BKV specific T cells
CMV/AdV /EBV/BKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes.
Three dose levels will be explored.
The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
|
Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD.
The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort.
If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with investigational product-related adverse events as assessed by CTCAE v4.03
Time Frame: 45 days for toxicity
|
The study will determine the optimal dose of intravenous injection of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, Adenovirus and BK virus( BKV) given to patients with or at risk for CMV, EBV, BK virus and adenovirus infection after cord blood transplant.
The safety will be assessed by investigational product-related adverse events as per CTCAE v4.03.
|
45 days for toxicity
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of CMV/AdV /EBV/BKV specific T cells will be measured by existence of cells in the system.
Time Frame: 12 months
|
To evaluate the impact of CTLs on CMV/AdV /EBV/BKV -specific T-lymphocyte immune reconstitution.
The impact will be evaluated by the number of months/years of cell survival.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHEERS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Viral Infection
-
Hospices Civils de LyonRecruiting
-
Materia Medica HoldingCompletedAcute Respiratory Viral InfectionRussian Federation
-
University of Wisconsin, MadisonCompletedRespiratory Viral InfectionUnited States
-
Sinovac Biotech Co., LtdWithdrawnInfection, Viral, EnterovirusChina
-
National Cancer Institute (NCI)CompletedViral InfectionsUnited States
-
Sinovac Biotech Co., LtdCompletedInfection, Viral, EnterovirusChina
-
National Institute of Allergy and Infectious Diseases...Completed
-
Xlear, IncMetanoic Health Ltd.Not yet recruitingRespiratory Viral Infection
-
University of Missouri-ColumbiaTerminatedRespiratory Viral InfectionUnited States
-
Istituto Giannina GasliniNot yet recruitingViral Infection After HSCT
Clinical Trials on CMV/AdV /EBV/BKV specific T cells
-
Prof. Tobias FeuchtingerEuropean Commission; Simbec-Orion Group Ltd, Merthyr Tydfil, UK; Miltenyi Biotec... and other collaboratorsRecruitingCMV Infection | EBV Infection | Stem Cell Transplant Complications | AdV InfectionBelgium, Spain, France, Germany, Italy, Netherlands
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedCytomegalovirus Infection | Adenovirus InfectionUnited States
-
University of Erlangen-Nürnberg Medical SchoolGerman Research Foundation; Charite University, Berlin, Germany; Ludwig-Maximilians... and other collaboratorsCompletedPatients Undergoing Allogeneic Stem Cell TransplantationGermany
-
Memorial Sloan Kettering Cancer CenterWithdrawnEBV Lymphomas | EBV-associated Malignancies
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedEpstein-Barr Virus InfectionsUnited States
-
AlloVirBaylor College of Medicine; The Methodist Hospital Research Institute; Center...WithdrawnAdenovirus InfectionUnited States
-
Central Hospital, Nancy, FranceCompleted
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Cell Medica LtdTechnology Strategy Board, United KingdomCompletedADV Infection Post Allo-HSCTUnited Kingdom
-
Baylor College of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); The Methodist... and other collaboratorsRecruitingLymphoma | Non-Hodgkin's Lymphoma | Hodgkin's Disease | Lymphoproliferative DiseaseUnited States